Drug Development/R&D

OHE publishes a report on the legal barriers to the better use of health data to deliver pharmaceutical innovation.

Two articles, published in the Journal of Comparative Effectiveness Research, explore the use of real-world evidence for coverage and formulary decisions.

Multi-Indication Pricing: Practical Solutions and Steps to Move Forward. A summary of an HTAi panel session.

The Center for Global Development and the Office of Health Economics are working on a new approach to drive the next generation of investment for better tuberculosis treatment. Our market-focused approach puts Brazil, Russia, India, China, and South Africa (the BRICS) governments in the driver’s seat—empowering them to send a powerful signal to private-sector pharmaceutical companies about the innovation they value and at the kind of price they are willing to consider.

OHE Lunchtime Seminar with Mariana Mazzucato on Re-imagining Health Innovation to Deliver Public Value. 28 September 2018 12:00-2:00pm.

To what extent can R&D incentives, competition and other factors facilitate access to highly valuable and costly pharmaceutical innovations?

What would be the price for an orphan drug that generate rates of return no greater/smaller than the industry average? Is it reasonable?

In this paper, Sir Geoffrey Owen and Dr Michael Hopkins discuss ‘The UK Biotech Sector and Brexit: Past Performance and Future Prospects’.

Just published are two new reports that explore the use of real world evidence for coverage and formulary decisions. The publications represent 1) the background paper to the 2017 ICER Membership Policy Summit and 2) a follow up paper based on the discussion at the Summit.

OHE has just published a new briefing entitled ‘Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help?’

Pages

Subscribe to RSS - Drug Development/R&D